FAQ/Help |
Calendar |
Search |
Today's Posts |
03-28-2009, 01:19 PM | #1 | ||
|
|||
Junior Member
|
Two questions:
Does this mean it's available to us while an eventual Phase III is ongoing? Is this not the very first non-dopaminergic compound (BIIB014 is an adenosine receptor antagonist) that will be available to us? http://www.medadnews.com/News/Index....ticleid=614883 "Biogen Idec also announced that it is currently in discussion with regulators surrounding the design of a registration program of BIIB014 in this patient population." Last edited by caldeerster; 03-28-2009 at 01:22 PM. Reason: typo - title should read BIIB014 |
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Biogen Reveals Another Tysabri PML Case | Multiple Sclerosis | |||
Salem Times-Register Article | Multiple Sclerosis | |||
Biogen CEO Comments on Tysabri | Multiple Sclerosis | |||
Rob Borsellino was a firebrand columnist for the Des Moines Register. He was a champi | ALS News & Research | |||
Okay folks. Where do I register to get back to the old children's neuro? | Children's Health |